In the conference they mention a surprise or secret announcement with Celgene. What could that surprise or secret be? Supposed to be announced at any time this year.
I'm not quite sure. It sounded positive, but "how positive" is the question. Since I'm not a scientist/drug specialist, I really don't know how to interpret it.
Evolving therapies to manage MS pain
Investigators are hoping to harness interleukin-10 (IL-10), a natural anti-inflammatory protein, in combating MS-related pain. Ordinarily, certain cells in the spine (called glial cells) regulate the transmission of pain signals, but in MS, these cells can become agitated and cause chronic pain in the spinal cord. Researchers hope that when the non-viral gene therapy that encodes IL-10 is delivered to the spinal fluid, cells in the area will produce the body’s own IL-10 and dampen pain signals.
Linda Watkins, PhD, chief scientific officer for Xalud Therapeutics and neuroscience professor at the University of Colorado, induced experimental autoimmune encephalomyelitis (EAE), an animal disease that mimics MS, in rats. “A non-viral gene therapy that produced IL-10 completely prevented central neuropathic pain, but what shocked everyone was that it reversed paralysis,” Dr. Watkins reports. “The rats had absolutely no motor impairments at the end of study and they didn’t relapse.”
But EAE progresses quickly in rats, leaving no time for long-term evaluations. Now, with Society funding, the project has expanded to mice, in which EAE progresses slowly. “We want to know if IL-10 injections only work after the first sign of pain, or if we can get results if the drug is administered much later,” Dr. Watkins says.
A compound known as C-21191 shows promise in a study funded by the Society, in collaboration with Concert Pharmaceuticals Inc. The hope is that C-21191 will reduce muscle spasms, stiffness (spasticity) and pain but without the sedation and coordination problems typically associated with current treatments, which often involve benzodiazepines, such as Ativan® (lorazepam) or Xanax® (alprazolam). The company is currently completing preclinical toxicology and pharmacology studies.
The future of pain treatment
Worldwide, 2.3 million people are living with MS and many must deal with pain. New discoveries and evolving studies are mo
But if the GSK deal didn't pan out, does that mean that deuterium doesn't work? They quit working on their hot flashes drug & other ones, too. They stopped at phase 1 on a hand full of drugs. Why would you stop working on a drug, and start working on other drugs instead?
Why? And why did they receive a milestone payment from them? And why have they invested more into Concert? The internet is missing too much information.
Concert has parlayed that concept into several partnerships with pharmaceutical companies. GlaxoSmithKline, Avanir Pharmaceuticals (NASDAQ: AVNR), Jazz Pharmaceuticals (NASDAQ: JAZZ), and most recently Celgene (NASDAQ: CELG) have all cut deals with Concert since 2009, though the GlaxoSmithKline deal didn’t pan out. Avanir, for instance, agreed to pay as much as $200 million for a license to use Concert’s technology to boost its drug for pseudobulbar affect, a condition that causes outbursts of crying or laughing. Jazz promised more than $120 million to Concert if it could soup up its narcolepsy drug, sodium oxybate (Xyrem). Those two deals have resulted in the drug candidates AVP-786 and JZP-386.
Seriously no one has anything to say? The stock just tanked & is going down in after hours a little more. ASPX tanked way harder, but is going up in after hours a decent amount. So what the hell is going on? Seriously?
Are you being serious or are you being picky about price? They'd have to sell you shares, just not at a price you might want.
what do you mean? Call the company & ask for information? I'm not sure they can say anything during the quiet period. Not even sure they'll answer the phone. I called one time, and some separate answering service machine picked up.
What license? Do the other invested bio-tech companies have a license with CNCE, too? Why just Celgene? What does having a license mean for these two companies?
Baku, Azerbaijan, Feb. 26
By Elena Kosolapova - Trend:
Kazakh National Agency for Technical Development received $498,865 from the sale of shares of Tetraphase Pharmaceuticals - a portfolio company of venture Flagship ventures fund 2004, the agency reported on Feb. 26.
In general the Fund distributed $7.6 million received from the deal among its investors.
This is the first distribution to investors since the fund creation.
The current portfolio of the venture fund consists of seven companies which are on sale now : BIND Biosciences., Inc., Concert Pharmaceuticals, Inc., Quanterix Corporation, T2 Biosystems, Inc., Black Duck, Inc., LS9, Inc. (Newco LS9, Inc), Mascoma Corporation.
Kazakh National Agency for Technical Development decided to finance the Fund. Flagship ventures fund 2004 in 2005. The fund invests in such areas as biotechnology, nanotechnology, medicine and information technology.
Edited by CN
Follow us on Twitter @TRENDNewsAgency
is it just hypothetical at this point? Certainly all these major investors had to have seen some kind of impressive proof, otherwise, why would they be investing so much. I don't know. I wish I knew that their medicine works for sure & that they're just trying to get it approved by the FDA. Who watched the retail roadshow presentation? Did they saying anything that would have led you to believe it really works for sure?
The stock was compared with ASPX. Common sense told me to buy at the open. Everyone saw what ASPX did. That should have created panic buying. Instead, the opposite happened. That's about as crazy as FB vs TWTR, only not as much downside as FB. FB is way better than Twitter, but TWTR soared, Facebook tanked. Makes no sense.